Cyclerion Therapeutics, Inc.
CYCN
$2.76
$0.2158.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -46.67% | -- | -- | -- | -69.03% |
| Gross Profit | 135.24% | -- | -- | -- | 69.03% |
| SG&A Expenses | 33.62% | -4.57% | -36.68% | -41.76% | -16.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.53% | -4.94% | -27.35% | -51.24% | -25.79% |
| Operating Income | -20.81% | 9.95% | 127.97% | 58.39% | 25.79% |
| Income Before Tax | 75.49% | 7.33% | 131.29% | 87.76% | 26.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.49% | 7.33% | 131.29% | 87.76% | 26.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.49% | 7.33% | 131.29% | -109.56% | 68.38% |
| EBIT | -20.81% | 9.95% | 127.97% | 58.39% | 25.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 79.97% | 9.57% | 129.84% | -109.21% | 71.25% |
| Normalized Basic EPS | -1.46% | 9.58% | 131.14% | 73.23% | 33.33% |
| EPS Diluted | 79.97% | 9.57% | 129.84% | -109.33% | 71.25% |
| Normalized Diluted EPS | -1.46% | 9.58% | 131.14% | 73.23% | 33.33% |
| Average Basic Shares Outstanding | 22.35% | 2.49% | 8.73% | 3.74% | 9.99% |
| Average Diluted Shares Outstanding | 22.35% | 2.49% | 8.73% | 3.74% | 9.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |